nitrazepam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1945 146-22-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrazadon
  • nitrazepam
  • neozepam
  • nitrodiazepam
A benzodiazepine derivative used as an anticonvulsant and hypnotic.
  • Molecular weight: 281.27
  • Formula: C15H11N3O3
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 87.28
  • ALOGS: -3.97
  • ROTB: 2

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.02 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 78 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.86 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enthesopathy 360.05 28.99 103 8125 7090 50589806
Tenosynovitis 320.99 28.99 103 8125 10462 50586434
Blood parathyroid hormone decreased 316.67 28.99 93 8135 7021 50589875
Tongue disorder 305.40 28.99 96 8132 9120 50587776
Panniculitis 300.30 28.99 93 8135 8410 50588486
Red blood cell sedimentation rate 280.49 28.99 73 8155 3513 50593383
Skin necrosis 277.87 28.99 93 8135 10774 50586122
Granuloma skin 271.89 28.99 79 8149 5739 50591157
Rheumatoid nodule 263.42 28.99 93 8135 12642 50584254
Tendonitis 242.37 28.99 94 8134 16611 50580285
Ulcer 221.71 28.99 93 8135 20107 50576789
Drug eruption 217.42 28.99 96 8132 23510 50573386
Hypercalcaemia 211.95 28.99 94 8134 23258 50573638
Basal cell carcinoma 205.52 28.99 92 8136 23264 50573632
C-reactive protein abnormal 196.25 28.99 94 8134 27715 50569181
Skin ulcer 174.99 28.99 94 8134 35224 50561672
Alanine aminotransferase abnormal 170.34 28.99 51 8177 4105 50592791
Red blood cell sedimentation rate increased 156.17 28.99 82 8146 29334 50567562
Psoriatic arthropathy 149.95 28.99 94 8134 46938 50549958
Fear of injection 147.13 28.99 50 8178 6053 50590843
Rash pruritic 143.48 28.99 92 8136 47754 50549142
Inflammation 133.61 28.99 94 8134 56818 50540078
Aspartate aminotransferase increased 125.92 28.99 103 8125 77895 50519001
Loss of personal independence in daily activities 124.77 28.99 98 8130 69952 50526944
Alanine aminotransferase increased 114.74 28.99 103 8125 88256 50508640
C-reactive protein increased 95.28 28.99 82 8146 66392 50530504
Drug tolerance decreased 86.66 28.99 38 8190 9122 50587774
Joint injury 86.03 28.99 50 8178 21739 50575157
Synovitis 80.78 28.99 100 8128 123765 50473131
Blood pressure systolic increased 77.25 28.99 56 8172 35393 50561503
Chest discomfort 75.65 28.99 84 8144 92638 50504258
Therapy non-responder 69.17 28.99 61 8167 50961 50545935
Erythema 66.25 28.99 99 8129 146315 50450581
Granuloma 62.20 28.99 25 8203 4833 50592063
Suicide attempt 53.09 28.99 53 8175 51679 50545217
Drug tolerance 51.50 28.99 22 8206 4954 50591942
Infusion related reaction 45.49 28.99 91 8137 169466 50427430
Retinal vein occlusion 39.85 28.99 14 8214 1867 50595029
Rheumatoid arthritis 38.81 28.99 95 8133 202455 50394441
Intellectual disability 38.03 28.99 11 8217 783 50596113
Peripheral swelling 37.78 28.99 95 8133 205841 50391055
Product use issue 37.44 28.99 78 8150 149397 50447499
Rheumatoid lung 36.16 28.99 14 8214 2451 50594445
Blood creatinine increased 35.09 28.99 52 8176 76108 50520788
Drug intolerance 34.02 28.99 95 8133 219009 50377887
Drug hypersensitivity 33.40 28.99 103 8125 250907 50345989
Pain in extremity 33.39 28.99 3 8225 272862 50324034
Angioplasty 33.07 28.99 11 8217 1244 50595652
Musculoskeletal disorder 32.40 28.99 25 8203 17324 50579572
Musculoskeletal stiffness 32.10 28.99 67 8161 128414 50468482
Contraindicated product administered 29.72 28.99 71 8157 148887 50448009
Limb injury 29.00 28.99 25 8203 20225 50576671

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tenosynovitis 275.84 25.03 73 4867 3660 29565927
Enthesopathy 275.65 25.03 73 4867 3670 29565917
Tongue disorder 233.07 25.03 67 4873 4569 29565018
C-reactive protein abnormal 218.66 25.03 69 4871 6467 29563120
Synovitis 198.86 25.03 73 4867 10817 29558770
Alanine aminotransferase abnormal 177.00 25.03 49 4891 2908 29566679
Tendonitis 162.63 25.03 58 4882 7903 29561684
Psoriatic arthropathy 128.21 25.03 58 4882 14633 29554954
Loss of personal independence in daily activities 125.21 25.03 68 4872 25372 29544215
Treatment failure 111.51 25.03 72 4868 36867 29532720
Drug hypersensitivity 93.53 25.03 83 4857 68323 29501264
Aspartate aminotransferase increased 92.86 25.03 78 4862 59647 29509940
Drug intolerance 78.93 25.03 65 4875 48314 29521273
Erythema 73.44 25.03 76 4864 75530 29494057
Alanine aminotransferase increased 70.13 25.03 72 4868 70872 29498715
Red blood cell sedimentation rate 51.40 25.03 13 4927 541 29569046
Granuloma skin 49.37 25.03 13 4927 635 29568952
Suicide attempt 47.73 25.03 42 4898 34068 29535519
Intentional overdose 47.16 25.03 44 4896 38484 29531103
Contraindicated product administered 46.34 25.03 32 4908 18234 29551353
Blood parathyroid hormone decreased 46.28 25.03 13 4927 811 29568776
Neuroleptic malignant syndrome 42.64 25.03 29 4911 16119 29553468
Panniculitis 41.23 25.03 13 4927 1208 29568379
Cor pulmonale acute 40 25.03 9 4931 225 29569362
Headache 38.91 25.03 88 4852 173919 29395668
Altered state of consciousness 37.22 25.03 29 4911 19860 29549727
C-reactive protein increased 35.03 25.03 40 4900 44223 29525364
Rheumatoid nodule 34.20 25.03 13 4927 2109 29567478
Procedural failure 31.21 25.03 6 4934 67 29569520
Hypersensitivity 30.86 25.03 41 4899 52862 29516725
Dystonia 26.91 25.03 18 4922 9731 29559856
Multiple-drug resistance 26.58 25.03 13 4927 3887 29565700
Compartment syndrome 25.62 25.03 11 4929 2441 29567146
Rhabdomyolysis 25.08 25.03 40 4900 60768 29508819

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enthesopathy 548.92 22.72 159 12464 9479 64476630
Tenosynovitis 516.73 22.72 159 12464 11674 64474435
Tongue disorder 463.31 22.72 147 12476 11933 64474176
Tendonitis 363.53 22.72 140 12483 20142 64465967
C-reactive protein abnormal 337.62 22.72 147 12476 28900 64457209
Alanine aminotransferase abnormal 332.39 22.72 100 12523 6788 64479321
Blood parathyroid hormone decreased 304.66 22.72 95 12528 7271 64478838
Panniculitis 287.21 22.72 95 12528 8784 64477325
Red blood cell sedimentation rate 278.33 22.72 76 12547 3638 64482471
Granuloma skin 262.39 22.72 81 12542 5993 64480116
Psoriatic arthropathy 261.87 22.72 140 12483 43141 64442968
Rheumatoid nodule 254.31 22.72 95 12528 12556 64473553
Skin necrosis 242.80 22.72 95 12528 14234 64471875
Loss of personal independence in daily activities 216.37 22.72 149 12474 72305 64413804
Ulcer 202.63 22.72 96 12527 22894 64463215
Synovitis 189.39 22.72 156 12467 98934 64387175
Drug eruption 180.33 22.72 103 12520 36033 64450076
Aspartate aminotransferase increased 179.25 22.72 164 12459 119624 64366485
Hypercalcaemia 174.29 22.72 96 12527 31320 64454789
Basal cell carcinoma 173.19 22.72 95 12528 30743 64455366
Alanine aminotransferase increased 147.82 22.72 158 12465 138873 64347236
Skin ulcer 146.87 22.72 97 12526 43877 64442232
Fear of injection 143.34 22.72 51 12572 5861 64480248
Rash pruritic 117.19 22.72 94 12529 57310 64428799
Inflammation 112.67 22.72 97 12526 65203 64420906
Red blood cell sedimentation rate increased 111.86 22.72 72 12551 31163 64454946
Erythema 111.71 22.72 159 12464 186911 64299198
C-reactive protein increased 104.56 22.72 110 12513 94799 64391310
Treatment failure 102.20 22.72 120 12503 116696 64369413
Drug intolerance 95.29 22.72 148 12475 187844 64298265
Drug hypersensitivity 93.49 22.72 167 12456 237648 64248461
Therapy non-responder 88.38 22.72 85 12538 65814 64420295
Joint injury 77.50 22.72 51 12572 22896 64463213
Contraindicated product administered 64.76 22.72 92 12531 107737 64378372
Drug tolerance decreased 57.89 22.72 28 12595 6970 64479139
Blood pressure systolic increased 57.43 22.72 59 12564 49394 64436715
Granuloma 53.22 22.72 26 12597 6615 64479494
Chest discomfort 52.69 22.72 87 12536 116019 64370090
Suicide attempt 47.74 22.72 64 12559 70943 64415166
Drug tolerance 46.31 22.72 23 12600 6062 64480047
Rheumatoid arthritis 43.54 22.72 98 12525 164196 64321913
Infusion related reaction 39.08 22.72 94 12529 164373 64321736
Neuroleptic malignant syndrome 38.80 22.72 35 12588 24961 64461148
Asthenia 38.27 22.72 18 12605 428026 64058083
Dyspnoea 38.24 22.72 51 12572 718623 63767486
Rheumatoid lung 36.96 22.72 15 12608 2464 64483645
Pain in extremity 35.39 22.72 8 12615 303077 64183032
Angioplasty 35.10 22.72 13 12610 1672 64484437
Salivary hypersecretion 33.95 22.72 24 12599 12089 64474020
Altered state of consciousness 33.19 22.72 39 12584 37863 64448246
Limb injury 32.77 22.72 31 12592 23474 64462635
Intentional overdose 32.49 22.72 61 12562 89883 64396226
Musculoskeletal stiffness 32.07 22.72 73 12550 123133 64362976
Peripheral swelling 31.30 22.72 101 12522 209052 64277057
Retinal vein occlusion 31.05 22.72 14 12609 2974 64483135
Cor pulmonale acute 29.85 22.72 9 12614 613 64485496
Musculoskeletal disorder 29.63 22.72 26 12597 17880 64468229
Procedural failure 29.28 22.72 6 12617 80 64486029
Psychiatric symptom 28.92 22.72 17 12606 6256 64479853
Back pain 28.42 22.72 7 12616 250164 64235945
Pneumonia aspiration 27.65 22.72 45 12578 59226 64426883
Product dose omission issue 27.54 22.72 3 12620 194744 64291365
Headache 26.12 22.72 185 12438 529282 63956827
Arthritis 25.62 22.72 53 12570 83761 64402348
Product use issue 25.21 22.72 76 12547 151639 64334470
Dystonia 24.63 22.72 24 12599 18841 64467268
Multiple-drug resistance 23.29 22.72 15 12608 6487 64479622
Choking 23.07 22.72 18 12605 10520 64475589

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD02 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:50268 GABA modulators
CHEBI has role CHEBI:53784 antispasmodics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Myoclonic seizure indication 37356005
Insomnia indication 193462001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.11 acidic
pKa2 2.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 8 WOMBAT-PK KEGG DRUG
GABA-A receptor; anion channel Ion channel IC50 7.42 CHEMBL

External reference:

IDSource
N0000166923 NUI
D00531 KEGG_DRUG
C0028126 UMLSCUI
CHEBI:7581 CHEBI
CHEMBL13209 ChEMBL_ID
DB01595 DRUGBANK_ID
D009567 MESH_DESCRIPTOR_UI
4506 PUBCHEM_CID
2121 INN_ID
9CLV70W7HS UNII
152070 RXNORM
003484 NDDF
387449001 SNOMEDCT_US
78449007 SNOMEDCT_US

Pharmaceutical products:

None